Investigating how a specific RNA regulates HIV gene expression and latency
Cytor lncRNA as a positive regulator of HIV gene expression and viral latency
This study is looking at how certain molecules in our cells, called long non-coding RNAs, might help control HIV hiding in the body, and it's for people living with HIV who want to understand new ways to tackle the virus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10681321 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of long non-coding RNAs (lncRNAs) in controlling HIV latency, which is crucial for eliminating the HIV reservoir in patients. The team will analyze the differences in RNA expression between activated and resting HIV-infected cells using advanced RNA sequencing techniques. They aim to identify specific lncRNAs, particularly one called Cytor, that may enhance HIV gene expression and influence viral latency. By studying how Cytor interacts with key cellular factors, the researchers hope to uncover new mechanisms that could lead to innovative treatments for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have a latent viral reservoir.
Not a fit: Patients who are not infected with HIV or those who have fully suppressed viral loads may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for reactivating latent HIV, potentially improving treatment outcomes for patients living with HIV.
How similar studies have performed: Previous research has shown that targeting non-coding RNAs can influence gene expression, suggesting that this approach may yield promising results.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Fujinaga, Koh — University of California, San Francisco
- Study coordinator: Fujinaga, Koh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.